← Leaderboards
Bruce G Redman
University Of Michigan At Ann Arbor
$679,712
Attributed
$679,712
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $23K · FY2005–07$25K$18.8K$12.5K$6.3K$0
'05
'06
'07
Funding mix
By agency
NIH$679,712 · 6
By mechanism
R01$620,388 · 1
M01$59,324 · 4
P30$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Alfred E Chang$7,481,608
- Laurence H Baker$13,775,401
- Yoichi Osawa$10,706,601
- Philip D King$12,120,681
- Kyung-Dall Lee$3,871,487
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationHuman SubjectPatient Oriented ResearchRenal Cell CarcinomaNeoplasm /Cancer ImmunotherapyClinical ResearchCell TransplantationNeoplasm /Cancer VaccineAutologous TransplantationNeoplasm /Cancer TherapyInterleukin 2DosageDrug Adverse EffectDrug Screening /EvaluationPharmacokineticsCombination Cancer TherapyNeoplasm /Cancer ChemotherapyLymph NodesMelanomaAntigen Presenting CellCellular ImmunityBiomedical FacilityHuman DataCd3 Molecule
Grant awards (12)
ADOPTIVE THERAPY OF RENAL CELL CARCINOMA WITH VACCINE-PRIMED LYMPHOCYTE$1,131
M01 · FY2007 · RR · contact PI
TUMOR-PULSED DENDRITIC CELL VACCINE W/ OR W/O IL-2 IN PTS W/METASTATIC MELANOMA$22,994
M01 · FY2006 · RR · contact PI
TUMOR-PULSED DENDRITIC CELL VACCINE W/ OR W/O IL-2 IN PTS W/METASTATIC MELANOMA$18,013
M01 · FY2005 · RR
Tumor-pulsed Dendritic Cell Vaccine w/ or w/o IL-2 in Pts w/Metastatic Melanoma$16,774
M01 · FY2004 · RR
T Cell Therapy of Human Renal Cell Cancer$306,803
R01 · FY2002 · CA
CORE--CLINICAL TRIALS OFFICE$0
P30 · FY2002 · CA
AUTOLOGOUS TUMOR PULSED FIBROCYTES AS TUMOR VACCINE IN PATIENTS W/ CANCER$0
M01 · FY2002 · RR
PHASE 1B STUDY OF CNI 1493 &IL 2 IN RENAL CELL CARCINOMA &MELANOMA$0
M01 · FY2002 · RR
T Cell Therapy of Human Renal Cell Cancer$313,585
R01 · FY2001 · CA
CORE--CLINICAL TRIALS OFFICE$0
P30 · FY2001 · CA
AUTOLOGOUS TUMOR PULSED FIBROCYTES AS TUMOR VACCINE IN PATIENTS W/ CANCER$206
M01 · FY2000 · RR
PHASE 1B STUDY OF CNI 1493 &IL 2 IN RENAL CELL CARCINOMA &MELANOMA$206
M01 · FY2000 · RR